Literature DB >> 23204477

Towards rational graft-versus-host disease prophylaxis.

Christoph M Bucher, Jakob R Passweg.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23204477      PMCID： PMC3590081          DOI： 10.3324/haematol.2012.080226

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.

Authors:  Laura Strauss; Theresa L Whiteside; Ashley Knights; Christoph Bergmann; Alexander Knuth; Alfred Zippelius
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

2.  A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Authors:  Joseph Pidala; Jongphil Kim; Heather Jim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Hugo F Fernandez; Marcie Tomblyn; Lia Perez; Janelle Perkins; Mian Xu; William E Janssen; Anandaraman Veerapathran; Brian C Betts; Frederick L Locke; Ernesto Ayala; Teresa Field; Leonel Ochoa; Melissa Alsina; Claudio Anasetti
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

3.  The EBMT activity survey: 1990-2010.

Authors:  J R Passweg; H Baldomero; A Gratwohl; M Bregni; S Cesaro; P Dreger; T de Witte; D Farge-Bancel; B Gaspar; J Marsh; M Mohty; C Peters; A Tichelli; A Velardi; C Ruiz de Elvira; F Falkenburg; A Sureda; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2012-04-30       Impact factor: 5.483

4.  Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

Authors:  Robert Zeiser; Dennis B Leveson-Gower; Elizabeth A Zambricki; Neeraja Kambham; Andreas Beilhack; John Loh; Jing-Zhou Hou; Robert S Negrin
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

5.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113
  5 in total
  1 in total

1.  Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.

Authors:  Marlies E H M Van Hoef
Journal:  Haematologica       Date:  2013-04       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.